WEBULL
WebtradeDownload

Exagen (XGN) Stock Jumps On Record Revenue But Profit Timing Remains Unclear

Simply Wall St · 1d ago

Exagen walked into this report as a small, loss making diagnostics stock that screens cheap on P/S and volatile on the chart. The market did not wait for the footnotes. The stock jumped about 38% to US$6.45 after earnings as investors reacted to a record quarter in autoimmune testing.

The headline is simple. Revenue reached US$19.9m in Q2, the highest in Exagen history, and adjusted EBITDA was almost at breakeven. Management also lifted full year 2026 revenue guidance to US$72m to US$75m, which is where the real debate now shifts.

Is Exagen a genuine bargain on a 1.7x P/S, or is the low multiple simply reflecting ongoing losses and slower revenue growth versus the market? Compare that gap directly in our valuation analysis for Exagen

Q2 2026 Earnings Summary

  • Revenue, Q2 2026 vs. Q2 2025: US$19.9m vs. US$17.2m (up about 16% year on year)
  • Net Loss, Q2 2026 vs. Q2 2025: US$3.2m loss vs. US$4.4m loss (loss narrowed by about 28%)
  • Basic EPS, Q2 2026 vs. Q2 2025: US$0.13 loss per share vs. US$0.21 loss per share (loss per share improved by about 37%)
  • Gross Margin, Q2 2026 vs. Q2 2025: about 61% vs. about 60% (improved by roughly 0.9 percentage points)

Prefer clean visual charts instead of another wall of earnings text and footnotes? View Exagen's full financial picture, including revenue trends, margins, and more, in the company report for Exagen.

NasdaqGM:XGN Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
NasdaqGM:XGN Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

Exagen’s Bull Case Hinges On Execution Milestones Hit

Bulls argue Exagen can grow into a higher margin autoimmune testing platform as adoption, pricing and pharma services all progress together. This quarter offers concrete proof in several of those areas. AVISE CTD volume hit a record with about 39,000 tests and more than 2,800 ordering clinicians, which backs the view that the franchise is getting deeper into rheumatology workflows. Trailing 12 month average selling price of US$446 per test, now higher for 13 consecutive quarters, and modest gross margin improvement to about 61% both support the pricing and revenue mix angle.

On profitability, adjusted EBITDA was almost breakeven, helped by operating expenses falling to roughly 70% of revenue. That lines up with the idea that operating leverage is starting to show. Finally, pharma services revenue above US$1m and backlog above US$6m confirm this higher margin stream is moving from theory to a measurable contributor.

Compare that internal step up in volumes, pricing and margins with how the NasdaqGM:XGN story is being marked to expectations. See the consensus price target analysis for Exagen to check whether analysts think this earnings progress supports the current share price reset.

Exagen Bears Still Waiting On Margin Proof

The core bearish concern on Exagen is that payer friction and a mixed customer base will cap average selling price and keep gross margins below the mid-60% target, which would delay sustained profitability. Q2 results do not fully counter that view. Gross margin is near 61%, and management now presents about 60% for 2026 as realistic, which is short of earlier mid-60% ambitions. That represents progress, but it still aligns with the bearish view that the business has more work to do on reimbursement and mix before margins can reset meaningfully higher.

Bears also argue that profitability will remain just out of reach. Adjusted EBITDA at roughly breakeven and cash generation of US$3.1 million are encouraging. However, management again linked breakeven to an US$80 million revenue level without providing a timeline. The absence of a dated profitability milestone keeps the execution risk argument in place.

After a 38% one-day move and no clear path to dated profitability, it is worth asking if these issues are isolated or part of a wider pattern of pressure points. Review the full risk analysis for Exagen which shows 2 important warning signs

Stay Ahead With Simply Wall St

If the Q2 revenue record and sharp one day move in Exagen have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a better entry point. Once you are invested, use the Portfolio Command Center to keep on top of the key developments that matter and filter out the rest. For longer term context and fresh angles on Exagen, tap into thousands of investor views through the Community. By spotting potential catalysts and risks early, you give yourself a better chance to stay ahead of the market.

Seeking Alternatives Beyond Exagen?

Fresh stock ideas move quickly. Some are building quiet breakout momentum while others are still flying under the radar for now. Do not get caught reacting late, get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.